New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
06:39 EDTBDSI, ENDPBioDelivery Sciences reports Bunavail PDUFA date of June 7
BioDelivery Sciences (BDSI) announced that in 2013, BDSI made important progress in significantly advancing and building its product portfolio in pain and addiction treatment and made meaningful strides in its continuing evolution from a development stage entity to a commercial enterprise. This included significant progress in the development of BDSI's two buprenorphine-containing products, BUNAVAIL for the maintenance treatment of opioid dependence and BEMA Buprenorphine, in partnership with Endo Pharmaceuticals, for the treatment of moderate to severe chronic pain. A New Drug Application, or NDA, for Bunavail was submitted to the FDA in mid-2013 and has a Prescription Drug User Fee Act, or PDUFA, date of June 7. In January, BDSI and Endo (ENDP) announced positive top-line results from the Phase 3 clinical trial of BEMA Buprenorphine in opioid naive patients. A second Phase 3 pivotal study for BEMA Buprenorphine, which is ongoing and being conducted in opioid experienced patients, is expected to report top-line results in mid-2014. In addition to the progress on its two buprenorphine containing products, BDSI expanded its product portfolio in 2013 by in-licensing Clonidine Topical Gel, a proposed treatment for painful diabetic neuropathy. Following a positive end of Phase 2 meeting with FDA in November, BDSI will begin this quarter enrolling patients in the first of two Phase 3 studies
News For BDSI;ENDP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 18, 2015
16:21 EDTENDPOn The Fly: Top stock stories for Monday
Stocks on Wall Street advanced in Monday trading, sending the Dow Jones Industrial Average and the S&P 500 to new all-time closing highs. The early part of the day saw the market move in a narrow range, but by early afternoon the market punched through its upper range and moved to session highs. The market drifted throughout the afternoon as the news flow was quiet and the trading volume remained light. ECONOMIC EVENTS: In the U.S., the National Association of Home Builders’ confidence index fell 2 points to a reading of 54 in May, missing expectations for a 1 point increase to a reading of 57. COMPANY NEWS: Shares of Apple (AAPL) advanced $1.47, or 1.14%, to $130.24 after noted investor Carl Icahn stated in an open letter to the company's CEO that he thinks other investors, analysts and the news media continue to misunderstand Apple and that its stock is "worth $240 today." Icahn urged Apple CEO Tim Cook to take advantage by launching a "much larger buyback" of the iPhone maker's shares. Separately, FBR Capital analysts Daniel Ives and James Moore wrote this morning in a note to investors that the Street is still underestimating Apple's growth outlook in China. The analysts believe that Apple's China revenue will exceed its revenue from the Americas in fiscal 2017... Endo International (ENDP) slid $4.53, or 5.31%, to $80.82 after the company agreed to pay $8B for privately held Par Pharmaceutical, which will roughly double Endo’s generics revenue and place its generics business among the top five as measured by U.S. sales. MAJOR MOVERS: Among the notable gainers was Ann Inc. (ANN), which surged $7.69, or 19.87%, to $46.40 after agreeing to be acquired by Ascena Retail Group (ASNA) for about $2.15B in cash and stock. Ascena, which agreed to pay $37.34 in cash and 0.68 of a share of its own common stock in exchange for each share of the parent of the Ann Taylor brand, slipped 14c, or 0.99%, to $14.07 after announcing the deal. Also higher was Achillion (ACHN), which rose $1.41, or 14.79%, to $10.98 after the company cancelled its presentation at the UBS Global Healthcare Conference. Conference cancellations often generate speculation as to whether a company is engaged in merger or acquisition talks. Among the noteworthy losers was Eleven Biotherapeutics (EBIO), which dropped $8.29, or 69.26%, to $3.68 after announcing the company’s Phase 3 study of its lead drug candidate, EBI-005, in moderate to severe dry eye disease did not meet either of its two co-primary endpoints. Also lower were shares of Weibo (WB), which fell 87c, or 5.24%, to $15.73 after the shares were downgraded to Hold from Buy at Summit Research. INDEXES: The Dow rose 26.32, or 0.14%, to 18,298.88, the Nasdaq gained 30.15, or 0.6%, to 5,078.44, and the S&P 500 added 6.47, or 0.3%, to 2,129.20.
14:42 EDTENDPAchillion rises as conference cancellation adds fuel to M&A speculation
Subscribe for More Information
09:20 EDTENDPEndo CEO says will be looking for deals on lower end of $300M-$1B range
Endo will be looking for deals similar to its Aspen transaction, the company's CEO added.
09:09 EDTENDPEndo says 'pretty large' disparity in FY16 interest expense view vs. consensus
Endo said it will not give FY16 guidance at this point but noted that there appears to be a "pretty large" disparity between the company's interest expense view for the fiscal year compared to what appears to be factored into the consensus FY16 forecast. Comments from Endo's call discussing its deal to acquire Par Pharmaceutical.
08:27 EDTENDPEndo says Par financing structure provides flexibility for future M&A
Endo expects adjusted diluted Par EPS to grow faster than revenues, according to slides for the Par Pharmaceutical acquisition presentation. Endo anticipates returns well in excess of its cost of capital, which should enable de-levering to a projected 3-4x net debt to EBITDA in 12-18 months. Endo said the financing structure of the Par deal provides flexibility for future M&A. Endo says consolidation and maturation of competitors have stabilized the generic pharmaceuticals pricing environment and that adding Par creates a top five generics player. Endo said it will have pro forma filed ANDAs of 165 and pro forma programs in development of 152 after adding Par.
06:36 EDTENDPEndo sees PAR transaction accretive to adjusted EPS in first 12 months
Subscribe for More Information
06:34 EDTENDPEndo to acquire Par Pharmaceutical in transaction valued at $8.05B
Endo and Par Pharmaceutical announced that they have entered into a definitive agreement under which Endo will acquire privately-held Par from TPG in a transaction valued at $8.05B, including assumption of Par debt. The combination is expected to help drive long-term double-digit revenue growth for Endo. The transaction has been unanimously approved by the boards of Endo and Par, and is supported by the management teams of both companies. There are no further shareholder approvals required. The purchase price will consist of approximately 18M shares, $1.55B of value based on the 10-day volume weighted average share price of Endo ending on May 15, of Endo equity and $6.50B cash consideration to Par shareholders. Endo has secured fully committed financing from Deutsche Bank and Barclays to fund the cash consideration. Endo expects to implement a permanent capital structure to finance the transaction prior to the close that would include a combination of cash, debt and an equity offering. The transaction is expected to close in the second half of 2015 and is subject to regulatory approval in the U.S. and certain other jurisdictions, as well as other customary closing conditions.
06:33 EDTENDPEndo to acquire Par Pharmaceutical in transaction valued at $8.05B
Subscribe for More Information
06:31 EDTENDPEndo to acquire Par Pharmaceutical in transaction valued at $8.05B
Subscribe for More Information
May 15, 2015
17:40 EDTENDPEndo announces FDA approval of label update for XIAFLEX
Subscribe for More Information
17:08 EDTENDPSoros Fund gives quarterly update on stakes
Subscribe for More Information
May 14, 2015
19:02 EDTENDP, BDSIOn The Fly: After Hours Movers
Subscribe for More Information
16:11 EDTENDP, BDSIEndo, BioDelivery announces Phase 3 data for buprenorphine
Subscribe for More Information
May 12, 2015
07:00 EDTBDSIBioDelivery Sciences price target lowered to $12 from $17 at Cantor
Subscribe for More Information
May 11, 2015
07:34 EDTENDPEndo acquires portfolio of branded and generic products from Aspen Holdings
Subscribe for More Information
07:16 EDTBDSIBioDelivery Sciences reports 11K prescriptions dispensed for Bunavail during Q1
Subscribe for More Information
07:16 EDTBDSIBioDelivery Sciences reports Q1 EPS (16c), consensus (19c)
Subscribe for More Information
07:13 EDTENDPEndo raises FY15 adjusted EPS to $4.40-$4.60 from $4.35-$4.55, consensus $4.48
Sees FY15 revenue $2.9B-$3B, consensus $2.99B. Sees FY15 adjusted gross margin of between 64%-65%. Sees FY15 effective tax rate of 13%-14%.
07:12 EDTENDPEndo reports Q1 US Branded Pharmaceuticals revenue $285M
Reports Q1 US Generic Pharmaceuticals revenue $357M. Reports Q1 International Pharmaceuticals revenue $73M.
07:11 EDTENDPEndo reports Q1 adjusted EPS $1.17, consensus $1.06
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use